Jiuling Yang
@jiulingy.bsky.social
Postdoc in the Blelloch lab at UCSF, cancer immunologist and pharmacologist, Umich PIBS-Pharmacology PhD, PKU medicine graduate, and a proud dog/plant/fish mom.
Reposted by Jiuling Yang
🚨 New Paper Alert! 🚨
Our latest study on KMT2C/KMT2D (mutated in 20% of cancers) reveals a new function for H3K4me1 in regulating DNA replication timing (RT) and origin activity during cell state transitions. Check it out: www.cell.com/cell-reports.... More info ⬇️
Our latest study on KMT2C/KMT2D (mutated in 20% of cancers) reveals a new function for H3K4me1 in regulating DNA replication timing (RT) and origin activity during cell state transitions. Check it out: www.cell.com/cell-reports.... More info ⬇️
KMT2C/KMT2D-dependent H3K4me1 mediates changes in DNA replication timing and origin activity during a cell fate transition
Gökbuget et al. use machine learning to quantify chromatin state changes that predict
DNA replication timing changes during cell differentiation. By following up on top
predictors through functional v...
www.cell.com
February 4, 2025 at 5:06 PM
🚨 New Paper Alert! 🚨
Our latest study on KMT2C/KMT2D (mutated in 20% of cancers) reveals a new function for H3K4me1 in regulating DNA replication timing (RT) and origin activity during cell state transitions. Check it out: www.cell.com/cell-reports.... More info ⬇️
Our latest study on KMT2C/KMT2D (mutated in 20% of cancers) reveals a new function for H3K4me1 in regulating DNA replication timing (RT) and origin activity during cell state transitions. Check it out: www.cell.com/cell-reports.... More info ⬇️
Reposted by Jiuling Yang
Excited about the release of my lab's first paper🎉https://shorturl.at/ftC4f today, in print soon. many thanks to @bwfund.bsky.social NICHD/NIH UCSFPathology, @mdphdequity.bsky.social #UCSFWatsonScholar UCSFLiverCenter @ucsfstemcell.bsky.social for support in the first year of sangokoyalab.ucsf.edu
The FIRE biosensor illuminates iron regulatory protein activity and cellular iron homeostasis
Iron is essential for life, yet the full context of its regulation in shaping cell
fates in stem cells of the early developing mammalian embryo is not well understood.
Sangokoya reports a ratiometric ...
shorturl.at
January 17, 2025 at 2:15 AM
Excited about the release of my lab's first paper🎉https://shorturl.at/ftC4f today, in print soon. many thanks to @bwfund.bsky.social NICHD/NIH UCSFPathology, @mdphdequity.bsky.social #UCSFWatsonScholar UCSFLiverCenter @ucsfstemcell.bsky.social for support in the first year of sangokoyalab.ucsf.edu
Reposted by Jiuling Yang
Excited to see this new #glycotime work from #proudofalumni Simon Wisnovsky's lab at UBC, identification of ST3GAL4 as mediator of Siglec-9 ligand biosynthesis in AML cells, which promotes immune evasion especially of macrophages.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9 - Leukemia
Leukemia - The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9
www.nature.com
November 19, 2024 at 7:37 AM
Excited to see this new #glycotime work from #proudofalumni Simon Wisnovsky's lab at UBC, identification of ST3GAL4 as mediator of Siglec-9 ligand biosynthesis in AML cells, which promotes immune evasion especially of macrophages.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Jiuling Yang
In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1
In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1
Chimeric antigen receptor (CAR) T cells are highly effective in hematologic malignancies. However, l
www.biorxiv.org
November 20, 2024 at 2:18 AM
In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma https://www.biorxiv.org/content/10.1101/2024.11.19.624352v1
Reposted by Jiuling Yang
Huaigeng is presenting his exciting work on developing cancer vaccines today at the UCSF Prostate Program retreat.
November 14, 2024 at 8:11 PM
Huaigeng is presenting his exciting work on developing cancer vaccines today at the UCSF Prostate Program retreat.
Reposted by Jiuling Yang
The Blelloch Lab held a retreat in the Tahoe National Forest this weekend. We decided to join the Bluesky Science Community.
November 11, 2024 at 5:50 AM
The Blelloch Lab held a retreat in the Tahoe National Forest this weekend. We decided to join the Bluesky Science Community.
I'm excited to share a new publication from my previous lab building on our earlier work on PROTAC degraders targeting MDM2 for cancer therapy. More efficient MDM2 degraders have been developed as we gain deeper insights into their mechanisms. Check it out if interested! pubs.acs.org/doi/full/10....
Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
MDM2 has been pursued as an attractive therapeutic target for human cancers. Herein, we describe our discovery of MD-265 as a promising PROTAC MDM2 degrader and extensive in vitro and in vivo evaluati...
pubs.acs.org
November 13, 2024 at 7:02 PM
I'm excited to share a new publication from my previous lab building on our earlier work on PROTAC degraders targeting MDM2 for cancer therapy. More efficient MDM2 degraders have been developed as we gain deeper insights into their mechanisms. Check it out if interested! pubs.acs.org/doi/full/10....